Find Locations
For hours, walk-ins and appointments.Unable to load global navigation.
Find Locations
For hours, walk-ins and appointments.
|
|
This test includes fluoxetine and norfluoxetine.
|
This test includes fluoxetine and norfluoxetine. |
3 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
3 |
3 days days |
Serum or plasma
2 mL
0.5 mL
Red-top tube, lavender-top (EDTA) tube, or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant. |
Red-top (no additive) tube or green-top (heparin) tube; gel-barrier tubes are not recommended |
Transfer separated serum or plasma to a plastic transport tube. Trough levels are most reproducible.
Transfer separated serum or plasma to a plastic transport tube. |
Transfer separated serum or plasma to a plastic transport tube. Trough levels are most reproducible. |
Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen.
|
Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen. |
Temperature | Period |
---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
This test is used for therapeutic drug management.
The efficacy of fluoxetine in the treatment of nondelusional, moderately depressed patients is comparable to that of the tricyclic agents; its efficacy in severely depressed hospitalized patients has not been established. In limited studies, fluoxetine was useful in treating patients with atypical depression, panic disorder, and the depressed component of bipolar disorder. Fluoxetine may be indicated as initial therapy in patients with concurrent obsessive-compulsive disorder. Its efficacy in obesity and bulimia is being explored. The selection of fluoxetine appears to be most appropriate for patients who are at special risk from sedative, hypotensive, and anticholinergic side effects caused by other antidepressants. In addition, it appears to be relatively safe for use in the elderly, although its very long elimination half-life may pose special problems for these individuals. |
This test is used for therapeutic drug management. |
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
Fluoxetine and norfluoxetine (combined total): 120–500 ng/mL
|
Fluoxetine and norfluoxetine (combined total): 120–500 ng/mL |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf